115 related articles for article (PubMed ID: 11006085)
21. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Wolf I; O'Kelly J; Rubinek T; Tong M; Nguyen A; Lin BT; Tai HH; Karlan BY; Koeffler HP
Cancer Res; 2006 Aug; 66(15):7818-23. PubMed ID: 16885386
[TBL] [Abstract][Full Text] [Related]
22. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer.
Liu Z; Wang X; Lu Y; Han S; Zhang F; Zhai H; Lei T; Liang J; Wang J; Wu K; Fan D
Carcinogenesis; 2008 Jun; 29(6):1219-27. PubMed ID: 18174234
[TBL] [Abstract][Full Text] [Related]
23. Androgen blocks apoptosis of hormone-dependent prostate cancer cells.
Kimura K; Markowski M; Bowen C; Gelmann EP
Cancer Res; 2001 Jul; 61(14):5611-8. PubMed ID: 11454715
[TBL] [Abstract][Full Text] [Related]
24. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Ding Y; Tong M; Liu S; Moscow JA; Tai HH
Carcinogenesis; 2005 Jan; 26(1):65-72. PubMed ID: 15358636
[TBL] [Abstract][Full Text] [Related]
25. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
26. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells.
Moreno J; Krishnan AV; Swami S; Nonn L; Peehl DM; Feldman D
Cancer Res; 2005 Sep; 65(17):7917-25. PubMed ID: 16140963
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
van der Poel HG
Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
[TBL] [Abstract][Full Text] [Related]
28. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
32. Reduced isoflavone metabolites formed by the human gut microflora suppress growth but do not affect DNA integrity of human prostate cancer cells.
Raschke M; Wähälä K; Pool-Zobel BL
Br J Nutr; 2006 Sep; 96(3):426-34. PubMed ID: 16925846
[TBL] [Abstract][Full Text] [Related]
33. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
Miyake H; Hara I; Gleave ME; Eto H
Prostate; 2004 Dec; 61(4):318-23. PubMed ID: 15389725
[TBL] [Abstract][Full Text] [Related]
34. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
Otani T; Yamaguchi K; Scherl E; Du B; Tai HH; Greifer M; Petrovic L; Daikoku T; Dey SK; Subbaramaiah K; Dannenberg AJ
Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G361-8. PubMed ID: 16195422
[TBL] [Abstract][Full Text] [Related]
35. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
Pérez-Palacios G; Santillán R; García-Becerra R; Borja-Cacho E; Larrea F; Damián-Matsumura P; González L; Lemus AE
J Endocrinol; 2006 Sep; 190(3):805-18. PubMed ID: 17003281
[TBL] [Abstract][Full Text] [Related]
36. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O
Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
39. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
40. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin.
Wolfgang CD; Essand M; Lee B; Pastan I
Cancer Res; 2001 Nov; 61(22):8122-6. PubMed ID: 11719440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]